Dan Ferris decode of his must have immediately stockSo Dan Ferris did share his pick with the paid Members within his Extreme Value newsletter on Stansbury But he also teased to the folks like me with a 49$ membership. Shockingly, its a doozy. It was up 20% today and isnt even close to being on the radar yet. I would be happy to […]
Articles
As
Lots and lots and lots of you have been asking me about the big “cancer presentation” that the Stansberry folks made last night, which apparently was a combination of Dr. David Eifrig’s medical advice and forecasting and Dave Lashmet’s hinting about his “medical breakthrough” stock… so let’s get to it. I did not watch or […]
Lots of readers have been sending questions our way about Porter Stansberry’s new high-cost Stansberry Venture Value newsletter, which is his attempt to build a service that essentially recommends small cap value stocks for long-term compounding value. An admirable goal, and I guess we’ll start to learn in the coming year or two how it’s […]
Dave Lashmet is sending around an ad for his Stansberry Venture service that he says highlights an investment that is “Three Times Better Than Any Opportunity I’ve Ever Found.” So that sounds pretty good, right? One nice thing about being an investment chatterer is that you can have a short memory — each idea that […]
Dave Lashmet has teased a handful of biotech stocks since starting the Stansberry Venture service a couple years ago, and they usually get a lot of attention from our readers — so the new ad from Lashmet today has been forwarded to me dozens of times already. And while I’m not sure we’ll be able […]
Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]
That’s a mysterious headline, right? The pitch we’re looking at today is from Dave Lashmet at Stansberry, who’s selling his Stansberry Venture newsletter for $5,000 — and the carrot he’s dangling to get you to subscribe is this “most disruptive biotech discovery” … which, it turns out, is a form of radiation therapy that, in […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Hello Folks, Anyone has a view/thoughts on the power elite investing program by Jon Markman?...
I must have horrible luck because I have found his advice to eat holes in my portfolio. My favorite to follow and trust ...
TMF has also recommended NXPI more than once. Good pick, at least until last year. The Weiss folks are best known fo...
Somebody complained about Jon Markman above. Losing money is certainly NOT the case recently not only on stocks but opti...
Hello, I am subscribed to TA for more than a year and I did quite a bit of analysis on his portfolio and picks before I...
Hello, I am subscribed to TA for more than a year and I did quite a bit of analysis on his portfolio and picks before I...
Hello, I am subscribed to TA for more than a year and I did quite a bit of analysis on his portfolio and picks before I...
I've read the above reviews with fascination, after receiving a Jon Markman promo and reading it today. The trend descri...
I've been with Trader's Advantage for about 6 months now. I've tried several other services in the past including Goril...
Jon Markman also noted both LUK and BAM a year or so ago, favorably comparing them to Berkshire (Better than Berkshire, ...